Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a not-for-profit organisation, founded in 2000 with the mission to perform research and provide scientific, economic and regulatory consultancy for innovation in the health sector at European level. The main fields of interest are life sciences and biotechnologies, drug development for small populations (pediatric and rare diseases), research management andmethodology, monitoring,statistics, regulatory, ethics and pharmacovigilance.

Who we are


Development and application of innovative methodologies in clinical trials for small populations, management of disease registries, execution of studies in the pharmacological field. Find out more.
Development and supervision of dossiers and documentation regarding national and European authorisation procedures for medicinal products. Find out more.
Development and management of all clinical trial phases, which are performed by the Consortium both as a Sponsor and as a Contract Research Organisation (CRO). Find out more.
Educational activities addressed to public bodies, research institutes and private companies, also within CME programmes. Find out more.
Management and participation to medical research projects and consortiums at national and international level. Find out more.
Design and management of registries and drug databases. Find out more.
Research networks aimed to facilitate transfer of know-how and to promote national and international research as well as scientific excellence. Find out more.

On-going Projects


Slide background
Slide background
Slide background
Slide background
NeoVanc LOGO crop
Closed logo
logo innermed

Latest News

2609, 2016

Paediatric formulations and Pharmas: closing day of the SMART Summer School

The last day of the SMART project’s Summer School, organized by Consorzio Valutazioni Biologiche e Farmacologiche moved to Canosa di Puglia, at the headquarters of Farmalabor, an Apulian company founded in 2001 with the aim of enhancing and spreading the culture of galenic formulations. To do so, it manufactures and markets raw materials (active ingredients and excipients), packaging and equipment necessary for the production of galenic drugs by pharmacies, hospitals, and national and international pharmaceutical companies. […]

2109, 2016

First Summer School of the SMART Project

The paediatric research asserts itself in Europe as a sector of great interest. It was estimated that for the Paediatric Regulation’s effect, the EMA (the European Medicines Agency), has launched about 800 new pediatric clinical trials that will require the involvement of 210,000 pediatric patients in the forthcoming years. […]